GlassScriptPhysician profile
Ronald D Alvarez
NPI 1689623167
$32,933.07
in general payments reported to CMS, 2019-2025
11 companies · $71.76 in 2025
The $71.76 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,905 · 2020: $2,640 · 2021: $14K · 2022: $8,250 · 2024: $2,774 · 2025: $71.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,740 · Food and Beverage: $79.69 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,740.00 |
| Food and Beverage | $79.69 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,843.63 | 2021-2024 | Lynparza |
| Myriad Genetic Laboratories, INC. | $4,200.00 | 2021-2022 | |
| Glaxosmithkline, LLC. | $3,262.50 | 2021 | |
| Eisai INC. | $3,025.00 | 2019 | |
| Genentech, INC. | $2,640.00 | 2020 | |
| Genentech USA, INC. | $1,330.00 | 2019 | |
| Abbvie INC. | $550.00 | 2019 | |
| Stryker Corporation | $30.11 | 2025 | Surgicount |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
| Daiichi Sankyo INC. | $15.95 | 2025 | Enhertu |
| Clovis Oncology, INC. | $10.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.